Clinical Trials · NCT05442450

Efficacy of Oral Semaglutide in Overweight or Obesity

UnknownPhase 4Semaglutide (Unclear)
Phase
Phase 4
Recruitment status
Unknown
Sponsor
Asian Institute of Gastroenterology, India
Enrollment
116
Start date
Jul 2022
Locations
1 site, India
Primary endpoint
The proportion of patients achieving a reduction in body weight of 5% or more from baseline
View Semaglutide compound reference